Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Bispecific antibodies for the treatment of tumours and infectious diseases

Bispecific antibodies for the treatment of tumours and infectious diseases Bispecific antibodies are in clinical and preclinical development for the treatment of various cancers and life-threatening infectious diseases. Designed to direct and enhance the body’s immune response to specific tumours and pathogens, bispecific antibodies have shown promising results in Phase I and Phase II clinical trials, leading in some cases to complete or partial responses in cancer patients. These bispecific antibodies consist of a ‘targeting’ domain, typically a fragment of a monoclonal antibody that binds to a tumour, linked to a ‘triggering’ arm that is specific for a molecule capable of mediating a phagocytic or lytic response by macrophages, natural killer cells, T-cells or other effector cells. By mediating an immune assault on tumours or pathogens, bispecific antibodies may also lead to antigen presentation and a vaccine-like response in patients. Over the next few years, we expect several bispecific antibodies to enter the late stages of clinical trials and ultimately emerge as new pharmaceutical products. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Expert Opinion on Investigational Drugs Taylor & Francis

Bispecific antibodies for the treatment of tumours and infectious diseases

Download PDF
10 pages

Loading next page...
 
/lp/taylor-francis/bispecific-antibodies-for-the-treatment-of-tumours-and-infectious-F10CELLgwK

References (75)

Publisher
Taylor & Francis
Copyright
© 1997 Ashley Publications Ltd.
ISSN
1744-7658
eISSN
1354-3784
DOI
10.1517/13543784.6.9.1169
Publisher site
See Article on Publisher Site

Abstract

Bispecific antibodies are in clinical and preclinical development for the treatment of various cancers and life-threatening infectious diseases. Designed to direct and enhance the body’s immune response to specific tumours and pathogens, bispecific antibodies have shown promising results in Phase I and Phase II clinical trials, leading in some cases to complete or partial responses in cancer patients. These bispecific antibodies consist of a ‘targeting’ domain, typically a fragment of a monoclonal antibody that binds to a tumour, linked to a ‘triggering’ arm that is specific for a molecule capable of mediating a phagocytic or lytic response by macrophages, natural killer cells, T-cells or other effector cells. By mediating an immune assault on tumours or pathogens, bispecific antibodies may also lead to antigen presentation and a vaccine-like response in patients. Over the next few years, we expect several bispecific antibodies to enter the late stages of clinical trials and ultimately emerge as new pharmaceutical products.

Journal

Expert Opinion on Investigational Drugs – Taylor & Francis

Published: Sep 1, 1997

Keywords: antigen presentation; bispecific antibodies; cancer; complement; cytotoxicity; Fc receptors; immunotherapy; infectious diseases; macrophages; monoclonal antibodies; monocytes; neutrophils; T-cells; tumours

There are no references for this article.